During the first half of 2026, the AI-driven pharmaceutical industry experienced a notable surge in growth potential, marked by a swift progression towards commercialization. The performance of the 'Three Little Dragons'—AI-driven pharmaceutical companies listed on the Hong Kong Stock Exchange—showed marked improvement: Insilico Medicine turned its financial situation around, moving from losses to profits; MediShield Technology enjoyed substantial revenue increases along with a significant decrease in adjusted net losses; and XtalPi's AI4S business segment saw remarkable growth. According to Choice data, as of August 30, among the 73 A-share AI-driven pharmaceutical (healthcare) concept stocks that have released their semi-annual financial results, more than half reported a year-on-year increase in net profit. The AI-driven pharmaceutical industry is rapidly transitioning from a phase of technological exploration to one of commercial value realization. The semi-annual reports highlight that frequent large-scale business development (BD) agreements have emerged as a key catalyst for the performance growth of listed companies.